Pharmacological Interventions for REM Sleep Behavior Disorder in Parkinson's Disease: A Systematic Review

Junqiang Yan(First Affiliated Hospital of Henan University of Science and Technology), Anran Liu(First Affiliated Hospital of Henan University of Science and Technology), Jiarui Huang(First Affiliated Hospital of Henan University of Science and Technology), Jiannan Wu(First Affiliated Hospital of Henan University of Science and Technology), Ruile Shen(First Affiliated Hospital of Henan University of Science and Technology), Hongxia Ma(First Affiliated Hospital of Henan University of Science and Technology), Jianxue Yang(First Affiliated Hospital of Henan University of Science and Technology)
Frontiers in Aging Neuroscience
August 13, 2021
10.3389/fnagi.2021.709878
Cited by 15Open Access
Full Text

Abstract

To review the therapeutic effects of drugs on REM sleep behavior disorder (RBD) in Parkinson's disease (PD) by searching the MEDLINE/PubMed, Embase, Cochrane, and CBM databases. According to the inclusion and exclusion criteria, studies were included after excluding duplicate data. We evaluated the safety and efficacy of pharmacological intervention to improve RBD in patients with Parkinson's disease (PD-RBD). This systematic review mainly describes the drugs that can be used to treat PD-RBD patients. The results have shown that melatonin can be used as the first-line drug for PD-RBD, and clonazepam provides significant improvement on PD-RBD, androtigotine can be used as an alternative drug. However, further large-scale clinical trial studies are still needed to provide the best guidelines for the pharmacological treatment of PD-RBD.

Related Papers

No related papers found

Powered by citation graph analysis